"Moderna's Next-Generation COVID-19 Vaccine Outperforms Current Shot in Phase 3 Trial"
TL;DR Summary
Moderna has reported positive interim results from the Phase 3 trial of its next-generation COVID-19 vaccine, mRNA-1283, showing a stronger immune response compared to its licensed COVID-19 vaccine, mRNA-1273.222. The new vaccine design offers potential storage advantages and paves the way for a combination vaccine against influenza and COVID-19. The trial demonstrated a higher immune response against both Omicron and original virus strains, particularly in participants over 65 years old. The vaccine's safety profile was found to be similar to Moderna's approved COVID-19 vaccines, and detailed trial data will be presented at upcoming events.
Topics:business#covid-19-vaccine#health-and-medicine#moderna#mrna-1283#next-generation-vaccine#phase-3-trial
- Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine Moderna Investor Relations
- Moderna Says New Covid Shot Hit Goal in Late-Stage Trial Bloomberg
- Moderna says new Covid vaccine showed stronger immune response than current shot in study NBC DFW
- Moderna’s New Covid-19 Vaccine Shows Positive Results Barron's
- Moderna's next-gen COVID vax surpasses approved version in phase 3 Fierce Biotech
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
3 min
vs 4 min read
Condensed
87%
748 → 94 words
Want the full story? Read the original article
Read on Moderna Investor Relations